CoTherix's Secondary Offering Could Pump New Blood Into Firm

CoTherix, strengthened by regulatory approval of its drug for pulmonary hypertension, filed a registration statement with the SEC for a 4 million-share offering. The secondary follows an initial public offering in October 2004 for the South San Francisco specialty pharmaceutical that raised $25.4 million for the company. At recent market prices the deal could raise roughly $44 million if underwriters exercise their 600,000-share overallotment.

San Francisco Business Times (http://www.bizjournals.com/sanfrancisco/stories/2005/01/24/newscolumn5.html)